CareDx, Inc (CDNA) Stock Score, Valuation & Financial Research
CareDx, Inc is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 41/100.
Quick answer for CDNA
CareDx, Inc currently has a Wall Street Score of 41/100. The stored market price is $52.64. Its financial score is 38/100. Its valuation score is 16/100. The latest WSS change is -0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What CareDx, Inc does
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific prime
CDNA financial snapshot
- Wall Street Score:
- 41/100
- Current price:
- $52.64
- Market capitalization:
- $2.72B
- Revenue:
- $458.1M
- Net income:
- $111.0M
- Free cash flow:
- $36.1M
- Cash:
- $373.6M
- Total debt:
- $19.2M
- EPS:
- 2.15
- P/E ratio:
- 24.5x
- Financial score:
- 38/100
- Valuation score:
- 16/100
- Revenue score:
- 46/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $36.1M, showing positive cash generation.
- The balance sheet shows $373.6M of cash versus $19.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.2 points: CDNA decreased 0.2 points because Capital declined by 2 points.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 38/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CDNA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.